利培酮治疗对急性未服药精神分裂症患者P50影响.docVIP

利培酮治疗对急性未服药精神分裂症患者P50影响【摘 要】 目的:探讨口服利培酮治疗对急性未服药精神分裂症患者听感觉门控P50的影响。方法:共纳入急性未服药精神分裂症患者64例(首发36例,复发28例),采用可变剂量利培酮治疗,分别于治疗前(基线期)及治疗8周后,采用听觉条件(S1)-测试(S2)刺激范式进行P50检测,同时使用阳性和阴性症状量表(the Positive and Negative Syndrome Scale,PANSS)评定患者精神病理症状;选取与患者性别、年龄、受教育年限匹配的健康人90例,测查P50作为正常对照。结果:①首发患者病程明显短于复发患者,但两者P50各指标无统计学差异。②与对照组相比,患者组(首发与复发合为患者组)基线期P50抑制率比值(S2/S1)升高[(36.0±32.0)% vs.(55.5±48.4)%](非正态分布)、S1波幅降低[(3.4±1.6)mV vs.(2.7±1.6)mV]、S1 与S2波幅差(S1-S2)减小[(2.2±1.6)ms vs.(1.3±1.3)ms],(P0.05);④在基线期患者组P50抑制率(S2/S1)与PANSS阴性量表分呈正相关(r=0.43,P=0.001);治疗8周后此相关性消失。结论:精神分裂症患者听感觉门控缺陷可能是精神分裂症稳定的内表型,与病程具有相对的独立性,利培酮难以改善这种缺陷。 【关键词】精神分裂症;听感觉门控P50;利培酮;精神病理症状;对照研究 中图分类号:R749.305 文献标识码:A 文章编号:1000-6729(2010)004-0265-05 doi:10.3969/j.issn.1000-6729.2010.04.006 Effects of risperidone on auditory gating potential P50 in acute medication-free patients with schizophrenia YANG Gui-Gang1,2,TAN Yun-Long?1,YANG Fu-De?1,LI Juan?1,CHEN Song?1, ZHANG Jing-Guo?1,WANG An-Wen?1,ZHANG Rong-Zhen?1,FENG Wei?1,WANG Zhi-Ren?1, ZHANG Wu-Fang?2,ZHOU Dong-Feng?2 ?1Beijing Huilongguan Hospital,Beijing 100096,China ?2Institude of Mental Health,Peking University;Key Laboratory of Mental Health,Ministry of Health (Peking University),Beijing 100191,China Corresponding author:ZHOU Dong-Feng,E-mail:zhoudf@bjmu.省略 【Abstract】 Objective:To investigate the effects of risperidone on sensory gating potential P50 in acute medication-free schizophrenics.Methods:Sixty-four acute medication-free schizophrenics(including 36 first-episode and 28 recurrent ones)were recorded of P50 and were evaluated of their psychopathic syndromes with the Positive and Negative Syndrome Scale(PANSS)before and after 8 weeks of medication with oral risperidone.And another 90 healthy persons’ P50 were collected as normal control data.Results:(1)There was no significant difference of P50 between the first-episode and recurrent schizophrenics regardless the former had shorter psychiatric course than the later.(2)Comparing with th